Moderna, Inc.
MRNA
You’ve read what changed. Here’s whether the market is confirming it.
Jodie situation report
Moderna, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 26 directly disclosed connections are confirming.
- MRNA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if MRNA's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind MRNA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
MRKMerck & Company, Inc.partnerMay 1, 2026 ▾
“We are advancing intismeran in collaboration with Merck, with eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types.”
IMTXImmatics N.V.partnerFeb 20, 2026 ▾
“We have also expanded our oncology portfolio with early-stage programs, including mRNA-4106 (a cancer antigen therapy), mRNA-2808 (a T-cell engager), and mRNA-4203 (a cell-therapy enhancer).”
Depended on by
PSNL25.0% of PSNLcustomerMay 7, 2026 ▾
“For example, we are providing genomic testing services to ModernaTX, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 23 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MRNA is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.